UFT/Leucovorin Plus Weekly Irinotecan in Advanced or Metastatic Colorectal Cancer
ByGeorgia Schilling, MD,Rainer Lipp, MD,Susanna Hegewisch-becker, MD, PhD,Dieter Kurt Hossfeld, MD, PhD
Published: | Updated:
This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer.